Southwest Pharmacy Residents

Leyken Wilson, PharmD

• Major Research Project: Tenecteplase versus Alteplase for Pulmonary Embolism
   

Faith Collum, PharmD

2025 – 2026 PGY1 Resident

• Major research project: Head, shoulders, knees and toes – Effects of adding nerve blocks to Zynrelef or Exparel on patient outcomes
• CE Seminar: Inpatient Delirium in Older Adults
• Changes to hospital or pharmacy practice made during PGY1 residency year:
• Inpatient Older Adult Acute Delirium Orderset
• Intravenous Immune Globulin (IVIG) medication use evaluation
• First position after finishing PGY1: MTM ambulatory care pharmacist for Methodist Health System

Jessica Doan, PharmD

2024 – 2025 PGY1 Resident

• Major research project: Evaluating the impact of a pharmacy auto-discontinuation protocol on vancomycin duration and adverse event
• CE Seminar: Review and aDAPT the Management of Percutaneous Coronary Intervention (PCI)
• Changes to hospital or pharmacy practice made during PGY1 residency year:
• Extravasation protocol
• Updated the stability of anti-neoplastic compounded agents chart
• First position after finishing PGY1: Oncology ambulatory care pharmacist at UTSW

Delilah Knapp, PharmD

2024 – 2025 PGY1 Resident

• Major research project: Assessing Variations in DKA Protocol Compliance and Safety Outcomes between emergency medicine and inpatient units
• CE Seminar: Hemophilia A/B and Von Willebrand Disease
• Changes to hospital or pharmacy practice made during PGY1 residency year:
• Updated pharmacy autosubstitution protocol with ten new drugs
• Created autosubstitution protocol for phosphate binders based on lab values
• Urine and blood culture pharmacist decision-making guideline
• First position after finishing PGY1: PGY2 Emergency Medicine Residency at Riverside University Health System
• Current Position: Emergency medicine pharmacist at Sharp Healthcare

Hannah Noxon, PharmD

2023 – 2024 PGY1 Resident

• Major research project: Treatment of mild to moderate diabetic ketoacidosis on an intermediate care unit utilizing a nursing-driven intravenous protocol
• CE Seminar: Evaluation of DOAC use in patients with altered gastrointestinal systems
• Changes to hospital or pharmacy practice made during PGY1 residency year:
• Updated pharmacy anticoagulation protocol
• Dornase alfa drug class review and MUE
• First position after finishing PGY1: PGY2 Critical Care Residency at University Health System
• Current position: Critical care pharmacist at Advocate Sherman Hospital

Rachel Chock, PharmD

2022 – 2023 PGY1 Resident

• Major research project: Clinical impact of a pharmacist-driven diabetes clinic on a suburban Dallas population in a “COVID-19 experienced” healthcare setting
• CE Seminar: ADA guideline update and pipeline drugs for diabetes
• Changes to hospital or pharmacy practice made during PGY1 residency year:
• Chemotherapy reference chart 
• Stability of reconstituted compounded items
• Palonosetron autosubstitution
• Retacrit auto-discontinuation policy MUE and formulary restriction update
• First position after finishing PGY1: Transitions of Care Pharmacist at UTSW
• Current position: Transplant pharmacist specialist at UTSW

Leandra Garcia, PharmD

2022 – 2023 PGY1 Resident

• Major research project: Evaluation of the use of tranexamic acid (TXA) for ACE inhibitor-induced angioedema in the emergency department 
• CE Seminar: ACE inhibitor-induced angioedema treatment
• Changes to hospital or pharmacy practice made during PGY1 residency year:
• RSI Order set
• Hypertonic saline IV administration guidelines update
• Sugammadex formulary addition
• First position after finishing PGY1: PGY2 Emergency Medicine Residency at UW Health SwedishAmerican Hospital
• Current position: Emergency medicine pharmacy specialist at MSWT and PRN emergency medicine pharmacist at Children’s Medical Center Dallas

Kevin Burnham, PharmD

2021 – 2022 PGY1 Resident

• Major research project: Utility assessment of a pharmacy to dose Daptomycin protocol: a retrospective cohort study
• CE Seminar: Review of antimicrobial-resistant gram negative infection (AMR 2.0) treatment guidelines
• Changes to hospital or pharmacy practice made during PGY1 residency year:
• Peripheral administration of hypertonic saline and mannitol
• Humate-P dosing and preparation review for pharmacists
• Kcentra formulary restriction updates and MUE
• Creation of hypertriglyceridemia-induced pancreatitis order set
• Creation of peritoneal dialysis order set including antimicrobials
• First position after finishing PGY1: Emergency medicine specialist at MSWT
• Current position: Entered medical school in 2025

Rubya Khalid, PharmD

2020 – 2021 PGY1 Resident

• Major research project: Comparison of vancomycin AUC outcomes – beyond the guidelines for serious MRSA infections
• CE Seminar: Anticoagulation use in COVID-19
• Changes to hospital or pharmacy practice made during PGY1 residency year:
• Creation of an argatroban-warfarin bridging treatment guideline
• First position after finishing PGY1: PRN Clinical pharmacist at MSWT
• Current position: PRN Clinical pharmacist at MSWT